Prognostic factors for early severe pulmonary complications after hematopoietic stem cell transplantation

Biology of Blood and Marrow Transplantation

Volumn 7, Issue 4, 2001, Pages 223-230

  Ho, Vincent T ^a   Weller, Edle ^a   Lee, Stephanie J ^a   Alyea, Edwin P ^a   Antin, Joseph H ^a   Soiffer, Robert J ^a,b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

Bone marrow transplantation; Diffuse alveolar hemorrhage; Pulmonary function tests; Pulmonary toxicity; T cell depletion

Indexed keywords

ACICLOVIR; BUSULFAN; CARBON MONOXIDE; CARMUSTINE; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETOPOSIDE; GANCICLOVIR; MELPHALAN; METHOTREXATE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADOPTIVE IMMUNOTHERAPY; ADULT; AGE; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; ARTIFICIAL VENTILATION; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CAUSE OF DEATH; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DONOR; FEMALE; FORCED EXPIRATORY VOLUME; GENDER; GRAFT VERSUS HOST REACTION; HEALTH STATUS; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INCIDENCE; INFECTIOUS PNEUMONIA; LUNG DIFFUSION CAPACITY; LUNG DISEASE; LUNG HEMORRHAGE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MORTALITY; MULTIVARIATE ANALYSIS; PNEUMOCYSTIS PNEUMONIA; PREDICTION; PROGNOSIS; RECIPIENT; RESPIRATORY FAILURE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEROTYPING; SMOKING; TOBACCO; WHOLE BODY RADIATION;

EID: 0035039140     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1053/bbmt.2001.v7.pm11349809     Document Type: Article

References (40)

1. Soubani A, Miller K, Hassoun P. Pulmonary complications of bone marrow transplantation. Chest. 1996;109:1066-1077.
2. Quabeck K. The lung as a critical organ in marrow transplantation. Bone Marrow Transplant. 1994;14(suppl 4):S19-S28.
3. Robbins R, Linder J, Stahl MG, et al. Diffuse alveolar hemorrhage in autologous bone marrow transplant recipients. Am J Med. 1989;87:511-518.
4. Kantrow SP, Hackman RC, Boeckh M, Myerson D, Crawford SW. Idiopathic pneumonia syndrome: changing spectrum of lung injury after marrow transplantation. Transplantation. 1997;63:1079-1086.
5. Wingard JR, Mellits ED, Sostrin MB, et al. Interstitial pneumonitis after allogeneic bone marrow transplantation: nine-year experience at a single institution. Medicine. 1988;67:175-186.
6. Granena A, Carreras E, Rozman C, et al. Interstitial pneumonitis after BMT: 15 years experience in a single institution. Bone Marrow Transplant. 1993;11:453-458.
7. Soiffer RJ, Murray C, Mauch P, et al. Prevention of graft-versus-host disease by selective depletion of CD6 positive T lymphocytes from donor marrow. J Clin Oncol. 1992;10:1191-1200.
8. Deeg HJ, Storb R, Thomas ED, et al. Cyclosporine as prophylaxis for graft-versus-host disease: a randomized study in patients undergoing marrow transplantation for nonlymphoblastic leukemia. Blood. 1985;65:1325-1334.
9. Storb R, Deeg HJ, Thomas ED, et al. Marrow transplantation for chronic myelocytic leukemia: a controlled trial of cyclosporine versus methotrexate for prophylaxis of graft-versus-host disease. Blood. 1985;66:698-702.
10. Goldman JM, Gale RP, Horowitz MM, et al. Bone marrow transplantation for chronic myelogenous leukemia in chronic phase. Increased risk for relapse associated with T-cell depletion. Ann Intern Med. 1988;108:806-814.
11. Kalbfleisch J, Prentice R. The Statistical Analysis of Failure Time Data. New York, NY: John Wiley and Sons; 1980.
12. Cox DR. Regression models and life tables. J R Stat Soc B. 1972; 34:187.
13. Kaplan E, Meier P. Non parametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457.
14. Breuer R, Or R, Lijovetzky G, et al. Interstitial pneumonitis in T-cell depleted bone marrow transplantation. Bone Marrow Transplant. 1988;3:625-630.
15. Cooke KR, Krobzik L, Martin TR, et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation, I: the roles of minor H antigens and endotoxin. Blood. 1996;88:3230-3239.
16. Cooke KR, Krenger W, Hill G, et al. Host reactive donor T cells are associated with lung injury after experimental allogeneic bone marrow transplantation. Blood. 1998;92:2571-2580.
17. Sparrelid E, Emanuel D, Fehniger T, Andersson U, Andersson J. Interstitial pneumonitis in bone marrow transplant recipients is associated with local production of TH2-type cytokines and lack of T-cell mediated cytotoxicity. Transplantation. 1997;63:1782-1789.
18. De Witte T, Gratwohl A, Van Der Lely N, et al. Recombinant human granulocyte-macrophage colony-stimulating factor accelerates neutrophil and monocyte recovery after allogeneic T-cell-depleted bone marrow transplantation. Blood. 1992;79:1359-1365.
19. Lee SJ, Weller E, Alyea EP, Ritz J, Soiffer RJ. Efficacy and costs of granulocyte colony-stimulating factor in allogeneic T-cell depleted bone marrow transplantation. Blood. 1998;92:2725-2729.
20. Linch DC, Scarffe H, Proctor S, et al. Randomised vehicle-controlled dose finding study of glycosylated recombinant human granulocyte colony-stimulating factor after bone marrow transplantation. Bone Marrow Transplant. 1993;11:307-311.
21. Spitzer G, Adkins DR, Spencer V, et al. Randomized study of growth factors post-peripheral-blood stem-cell transplant: neutrophil recovery is improved with modest clinical benefit. J Clin Oncol. 1994;12:661-670.
22. Klumpp TR, Mangan KF, Goldberg SL, Pearlman ES, Macdonald JS. Granulocyte colony-stimulating factor accelerates neutrophil engraftment following peripheral-blood stem-cell transplantation: a prospective, randomized trial. J Clin Oncol. 1995;13:1323.
23. McQuaker IG, Hunter AE, Pacey S, Haynes AP, Iqbal A, Russell NH. Low-dose filgrastim significantly enhances neutrophil recovery following autologous peripheral-blood stem-cell transplantation in patients with lymphoproliferative disorders: evidence for clinical and economical benefits. J Clin Oncol. 1997;15:451-457.
24. Advani R, Chao NJ, Horning SJ, et al. Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct to autologous hemopoietic stem cell transplantation for lymphoma. Ann Intern Med. 1992;116:183-189.
25. Nemunaitis J, Buckner CD, Appelbaum FR, et al. Phase I/II trial of recombinant human granulocyte-macrophage colony-stimulating factor following allogeneic bone marrow transplantation. Blood. 1991;77:2065-2071.
26. Shriber JR, Chao NJ, Long GD, et al. Granulocyte colony-stimulating factor after allogeneic bone marrow transplantation. Blood. 1994;84:1680-1684.
27. Nemunaitis J, Anasetti C, Buckner CD, et al. Long-term follow-up of 103 patients who received recombinant human granulocyte-macrophage colony-stimulating factor after unrelated donor bone marrow transplantation [letter]. Blood. 1992;81:865.
28. Nemunaitis J, Anasetti C, Storb R, et al. Phase II trial of recombinant human granulocyte-macrophage colony-stimulating factor in patients undergoing allogeneic bone marrow transplantation from unrelated donors. Blood. 1992;79:2572-2577.
29. Nemunaitis J, Rosenfeld CS, Ash R, et al. Phase III randomized, double-blind placebo-controlled trial of rhGM-CSF following allogeneic bone marrow transplantation. Bone Marrow Transplant. 1995;15:949-954.
30. Powles R, Smith C, Milan S, et al. Human recombinant GM-CSF in allogeneic bone marrow transplantation for leukaemia: double-blind, placebo-controlled trial. Lancet. 1990;336:1417-1420.
31. Drobyski WR, Ash RC, Casper JT, et al. Effect of T-cell depletion as graft-versus-host disease prophylaxis on engraftment, relapse, and disease free survival in unrelated marrow transplantation for chronic myelogenous leukemia. Blood. 1994;83:1980-1987.
32. Katoh M, Shikoshi K, Takada M, et al. Development of interstitial pneumonitis during treatment with granulocyte colony-stimulating factor. Ann Hematol. 1993;67:201-202.
33. Kitayama H, Ishikawa J, Yamagami T, et al. Granulocyte colony-stimulating factor in allogeneic bone marrow transplantation. Jpn J Clin Oncol. 1989;19:367-372.
34. Hasegawa Y, Ninomiya H, Kamoshita M, et al. Interstitial pneumonitis related to granulocyte colony-stimulating factor administration following chemotherapy for elderly patients with non-Hodgkin's lymphoma. Intern Med. 1997;36:360-364.
35. Soiffer R, Rabinowe S, Anderson K, et al. Low incidence of hepatic veno-occlusive disease (VOD) after cyclophosphamide/ fractionated TB1 and T cell depleted allogeneic BMT [abstract]. Blood. 1990;76(suppl 1):566a.
36. Soiffer RJ, Dear K, Rabinowe SN, et al. Hepatic dysfunction following T-cell-depleted allogeneic bone marrow transplantation. Transplantation. 1991;52:1014-1019.
37. Gruss E, Bernis C, Tomas JF, et al. Acute renal failure in patients following bone marrow transplantation: prevalence, risk factors and outcome. Am J Nephrol. 1995;15:473-479.
38. Crawford S, Fisher L. Predictive value of pulmonary function tests before marrow transplantation. Chest. 1992;101:1257-1264.
39. Goldberg SL, Klumpp TR, Magdalinski AJ, Mangan KF. Value of pretransplant evaluation in predicting day 100 mortality among blood stem cell and bone marrow transplant recipients. J Clin Oncol. 1998;16:3796-3802.
40. Horak DA, Schmidt GM, Zaia JA, Niland JC, Ahn C, Forman SJ. Pretransplant pulmonary function predicts cytomegalovirus-associated interstitial pneumonia following bone marrow transplantation. Chest. 1992;102:1484-1490.